The overarching theme of my research is to leverage genomics, genetics, and translational data to uncover the molecular mechanisms driving disease progression and develop precision medicine strategies. My current focus explores the interplay between somatic and inherited genetic factors in cardiovascular and neurological diseases, emphasizing brain, heart, and blood interactions. This includes investigating the genetic contributions to heart failure (HF), coronary artery disease (CAD), thoracic aortic aneurysms (TAA), and cardiotoxicity associated with cancer therapies, particularly immune checkpoint inhibitor (ICI)-induced myocarditis. A key area of interest is somatic mutations such as clonal hematopoiesis of indeterminate potential (CHIP), which I study in relation to cardiovascular dysfunction and treatment-induced cardiac injury. By integrating genetic data with advanced imaging modalities, including cardiac and brain MRI, my work aims to elucidate the shared pathways that connect cardiovascular and neurological conditions and uncover early imaging biomarkers of therapy-related toxicity. My previous research spans multiple domains, including the study of neural tube defects through the analysis of trio data, which has provided insights into the role of somatic mosaicism in congenital anomalies. Additionally, I have developed novel polygenic and partitioned risk scores (PRS and PGRS), applied in diseases such as multiple sclerosis (MS) and Alzheimer's disease (AD), to uncover the genetic architecture underlying these complex disorders. These methodologies enable stratified risk prediction and personalized treatment approaches, bridging the gap between genotype and phenotype. I have also investigated brain-heart interactions, particularly the shared genetic and metabolic pathways linking neurological and cardiovascular diseases, as well as the effects of somatic mutations and ICI therapies on myocardial inflammation and cardiac outcomes. My studies have revealed critical biomarkers and causal variants for diseases like HF and TAA, with a focus on their downstream impact on clinical outcomes, therapy response, and adverse treatment effects. My contributions to islet biology in type 2 diabetes (T2D) through large consortia such as HPAP and IIDP have further refined our understanding of disease physiology, supporting therapeutic advancements. Currently, I am integrating insights from neural tube defect studies, MS research, brain-heart interaction models, and immunotherapy-induced cardiotoxicity into a comprehensive framework that connects somatic mutations, genetic risk, treatment effects, and imaging-based phenotypes. This interdisciplinary approach provides a foundation for personalized medicine, offering targeted strategies to manage cardiovascular, neurological, and metabolic diseases while addressing therapy-related cardiac complications.
EMR and EHR systems for cancer research and integrated genomics.
Medical Images segmentation and noise removal,computer vision and Imaging informatics.